Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac more
Time Frame | BNTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.06% | -2.12% | -3% |
1-Month Return | 10.71% | -3.42% | -0.73% |
3-Month Return | 0.71% | -11.13% | 2.87% |
6-Month Return | 31.67% | -5.74% | 7.17% |
1-Year Return | 10% | 3.97% | 25.31% |
3-Year Return | -58.91% | 1.05% | 28.38% |
5-Year Return | 223.36% | 34.37% | 81.89% |
10-Year Return | 694.1% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 108.59M | 482.32M | 18.98B | 17.31B | 3.82B | [{"date":"2019-12-31","value":0.57,"profit":true},{"date":"2020-12-31","value":2.54,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.22,"profit":true},{"date":"2023-12-31","value":20.12,"profit":true}] |
Cost of Revenue | 243.83M | 704.36M | 3.86B | 4.53B | 599.80M | [{"date":"2019-12-31","value":5.38,"profit":true},{"date":"2020-12-31","value":15.54,"profit":true},{"date":"2021-12-31","value":85.19,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":13.23,"profit":true}] |
Gross Profit | (135.24M) | (222.04M) | 15.12B | 12.78B | 3.22B | [{"date":"2019-12-31","value":-0.89,"profit":false},{"date":"2020-12-31","value":-1.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.54,"profit":true},{"date":"2023-12-31","value":21.3,"profit":true}] |
Gross Margin | (124.54%) | (46.03%) | 79.66% | 73.82% | 84.29% | [{"date":"2019-12-31","value":-147.75,"profit":false},{"date":"2020-12-31","value":-54.61,"profit":false},{"date":"2021-12-31","value":94.5,"profit":true},{"date":"2022-12-31","value":87.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 46.28M | (139.62M) | 200.10M | 135.90M | 2.53B | [{"date":"2019-12-31","value":1.83,"profit":true},{"date":"2020-12-31","value":-5.52,"profit":false},{"date":"2021-12-31","value":7.91,"profit":true},{"date":"2022-12-31","value":5.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (181.52M) | (82.42M) | 15.28B | 12.64B | 690.40M | [{"date":"2019-12-31","value":-1.19,"profit":false},{"date":"2020-12-31","value":-0.54,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.72,"profit":true},{"date":"2023-12-31","value":4.52,"profit":true}] |
Total Non-Operating Income/Expense | 1.81M | (66.89M) | (263.20M) | 622.80M | 845.40M | [{"date":"2019-12-31","value":0.21,"profit":true},{"date":"2020-12-31","value":-7.91,"profit":false},{"date":"2021-12-31","value":-31.13,"profit":false},{"date":"2022-12-31","value":73.67,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (179.44M) | (145.80M) | 15.05B | 12.95B | 1.19B | [{"date":"2019-12-31","value":-1.19,"profit":false},{"date":"2020-12-31","value":-0.97,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.09,"profit":true},{"date":"2023-12-31","value":7.88,"profit":true}] |
Income Taxes | (268.00K) | (161.00M) | 4.75B | 3.52B | 255.80M | [{"date":"2019-12-31","value":-0.01,"profit":false},{"date":"2020-12-31","value":-3.39,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":74.04,"profit":true},{"date":"2023-12-31","value":5.38,"profit":true}] |
Income After Taxes | (179.17M) | 15.20M | 10.29B | 9.43B | 930.30M | [{"date":"2019-12-31","value":-1.74,"profit":false},{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true}] |
Income From Continuous Operations | (179.17M) | 15.20M | 10.29B | 9.43B | 930.30M | [{"date":"2019-12-31","value":-1.74,"profit":false},{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (179.17M) | 15.20M | 10.29B | 9.43B | 930.30M | [{"date":"2019-12-31","value":-1.74,"profit":false},{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true}] |
EPS (Diluted) | (0.39) | 0.07 | 39.69 | 36.93 | 3.83 | [{"date":"2019-12-31","value":-0.98,"profit":false},{"date":"2020-12-31","value":0.18,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.05,"profit":true},{"date":"2023-12-31","value":9.65,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
BNTX | |
---|---|
Cash Ratio | 6.62 |
Current Ratio | 7.33 |
Quick Ratio | 7.21 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BNTX | |
---|---|
ROA (LTM) | -1.24% |
ROE (LTM) | -2.40% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BNTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.15 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.85 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BNTX | |
---|---|
Trailing PE | NM |
Forward PE | 7.04 |
P/S (TTM) | 8.78 |
P/B | 1.33 |
Price/FCF | NM |
EV/R | 2.95 |
EV/Ebitda | 110.81 |
PEG | 0.04 |
BioNTech SE (BNTX) share price today is $113.08
Yes, Indians can buy shares of BioNTech SE (BNTX) on Vested. To buy BioNTech SE from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BNTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of BioNTech SE (BNTX) via the Vested app. You can start investing in BioNTech SE (BNTX) with a minimum investment of $1.
You can invest in shares of BioNTech SE (BNTX) via Vested in three simple steps:
The 52-week high price of BioNTech SE (BNTX) is $131.49. The 52-week low price of BioNTech SE (BNTX) is $76.53.
The price-to-earnings (P/E) ratio of BioNTech SE (BNTX) is
The price-to-book (P/B) ratio of BioNTech SE (BNTX) is 1.33
The dividend yield of BioNTech SE (BNTX) is 0.00%
The market capitalization of BioNTech SE (BNTX) is $26.76B
The stock symbol (or ticker) of BioNTech SE is BNTX